

Susan P Mollan

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5417688/publications.pdf>

Version: 2024-02-01

123
papers

4,411
citations

126858

33
h-index

123376

61
g-index

133
all docs

133
docs citations

133
times ranked

2506
citing authors

#	ARTICLE	IF	CITATIONS
1	Predicting the immediate impact of national lockdown on neovascular age-related macular degeneration and associated visual morbidity: an INSIGHT Health Data Research Hub for Eye Health report. <i>British Journal of Ophthalmology</i> , 2023, 107, 267-274.	2.1	5
2	Optical coherence tomography confirms shunt malfunction and recurrence of raised intracranial pressure in optic atrophy. <i>British Journal of Neurosurgery</i> , 2022, 36, 185-191.	0.4	6
3	Obstructive sleep apnoea in women with idiopathic intracranial hypertension: a sub-study of the idiopathic intracranial hypertension weight randomised controlled trial (IIH: WT). <i>Journal of Neurology</i> , 2022, 269, 1945-1956.	1.8	17
4	Cerebrospinal fluid shunting protocol for idiopathic intracranial hypertension for an improved revision rate. <i>Journal of Neurosurgery</i> , 2022, 136, 1790-1795.	0.9	8
5	Dr Gordon Plant's Festschrift Tidings. <i>Neuro-Ophthalmology</i> , 2022, 46, 1-7.	0.4	0
6	An update on the clinical approach to giant cell arteritis. <i>Clinical Medicine</i> , 2022, 22, 107-111.	0.8	2
7	Managing idiopathic intracranial hypertension in pregnancy: practical advice. <i>Practical Neurology</i> , 2022, 22, 295-300.	0.5	17
8	Increased systemic and adipose 11 β -HSD1 activity in idiopathic intracranial hypertension. <i>European Journal of Endocrinology</i> , 2022, 187, 323-333.	1.9	11
9	Idiopathic intracranial hypertension: Evaluation of births and fertility through the Hospital Episode Statistics dataset. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2022, 129, 2019-2027.	1.1	17
10	Erenumab for the treatment of chronic migraine with idiopathic intracranial hypertension in ocular remission. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A74.1-A74.	0.9	0
11	Calcitonin gene-related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A119.2-A119.	0.9	0
12	Negative impact of COVID-19 lockdown on papilloedema and idiopathic intracranial hypertension. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A121.2-A121.	0.9	1
13	Intracranial pressure determines headache morbidity in idiopathic intracranial hypertension. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A117.1-A117.	0.9	0
14	How much weight loss is required to reduce intracranial pressure in idiopathic intracranial hypertension?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A116.4-A117.	0.9	0
15	Bariatric surgery versus community weight management intervention for idiopathic intracranial hypertension: a randomised controlled trial. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, A98.1-A98.	0.9	0
16	Association of Amount of Weight Lost After Bariatric Surgery With Intracranial Pressure in Women With Idiopathic Intracranial Hypertension. <i>Neurology</i> , 2022, 99, .	1.5	22
17	Eosinophilic Granulomatosis with Polyangiitis Presenting as Unilateral Acute Anterior Ischaemic Optic Neuropathy. <i>Neuro-Ophthalmology</i> , 2021, 45, 109-116.	0.4	1
18	Practice points for ophthalmologists from the 2020 British Society for Rheumatology Giant Cell Arteritis guidelines. <i>Eye</i> , 2021, 35, 699-701.	1.1	5

#	ARTICLE	IF	CITATIONS
19	Erenumab for headaches in idiopathic intracranial hypertension: A prospective open-label evaluation. <i>Headache</i> , 2021, 61, 157-169.	1.8	31
20	11 β HSD1 Inhibition with AZD4017 Improves Lipid Profiles and Lean Muscle Mass in Idiopathic Intracranial Hypertension. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021, 106, 174-187.	1.8	39
21	Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. <i>Lancet Rheumatology</i> , The, 2021, 3, e71-e82.	2.2	18
22	Cognitive performance in idiopathic intracranial hypertension and relevance of intracranial pressure. <i>Brain Communications</i> , 2021, 3, fcab202.	1.5	26
23	Idiopathic Intracranial Hypertension and Anemia: A Matched Case-Control Study. <i>Journal of Neuro-Ophthalmology</i> , 2021, 41, e272-e273.	0.4	0
24	Telemetric monitoring in idiopathic intracranial hypertension demonstrates intracranial pressure in a case with sight-threatening disease. <i>Acta Neurochirurgica</i> , 2021, 163, 725-731.	0.9	6
25	Headache for ophthalmologists: current advances in headache understanding and management. <i>Eye</i> , 2021, 35, 1574-1586.	1.1	7
26	The Potentially Modifiable Risk Factor in Idiopathic Intracranial Hypertension. <i>Neurology: Clinical Practice</i> , 2021, 11, e504-e507.	0.8	38
27	The Health Economic Evaluation of Bariatric Surgery Versus a Community Weight Management Intervention Analysis from the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT). <i>Life</i> , 2021, 11, 409.	1.1	6
28	"IIH Pressure" a randomised, controlled, double blind physiology study of the effect of Exenatide on intracranial pressure. <i>BMJ Military Health</i> , 2021, 167, e1.2-e1.	0.4	4
29	Current Perspectives on Idiopathic Intracranial Hypertension without Papilloedema. <i>Life</i> , 2021, 11, 472.	1.1	10
30	The Role of Metabolism in Migraine Pathophysiology and Susceptibility. <i>Life</i> , 2021, 11, 415.	1.1	14
31	Systemic and adipocyte transcriptional and metabolic dysregulation in idiopathic intracranial hypertension. <i>JCI Insight</i> , 2021, 6, .	2.3	45
32	Idiopathic Intracranial Hypertension: Evaluation of Admissions and Emergency Readmissions through the Hospital Episode Statistic Dataset between 2002-2020. <i>Life</i> , 2021, 11, 417.	1.1	37
33	Outcomes measures in idiopathic intracranial hypertension. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 687-700.	1.4	12
34	Effectiveness of Bariatric Surgery vs Community Weight Management Intervention for the Treatment of Idiopathic Intracranial Hypertension. <i>JAMA Neurology</i> , 2021, 78, 678.	4.5	86
35	Headache attributed to idiopathic intracranial hypertension and persistent post-idiopathic intracranial hypertension headache: A narrative review. <i>Headache</i> , 2021, 61, 808-816.	1.8	37
36	Cost-effectiveness of bariatric surgery versus community weight management to treat obesity-related idiopathic intracranial hypertension: evidence from a single-payer healthcare system. <i>Surgery for Obesity and Related Diseases</i> , 2021, 17, 1310-1316.	1.0	15

#	ARTICLE	IF	CITATIONS
37	Current Perspective on Retinal Migraine. <i>Vision (Switzerland)</i> , 2021, 5, 38.	0.5	5
38	Negative impact of COVID-19 lockdown on papilloedema and idiopathic intracranial hypertension. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 795-797.	0.9	28
39	Intracranial pressure directly predicts headache morbidity in idiopathic intracranial hypertension. <i>Journal of Headache and Pain</i> , 2021, 22, 118.	2.5	33
40	Response to "Magnetic resonance or computed tomography venography in the evaluation of young overweight women with papilledema". <i>Eye</i> , 2021, 35, 3453-3454.	1.1	0
41	Teaching NeuroImages: Distinguishing Papilledema From Pseudopapilledema Using Optical Coherence Tomography. <i>Neurology</i> , 2021, 96, e2666-e2667.	1.5	0
42	Current advances in giant cell arteritis. <i>Current Opinion in Neurology</i> , 2021, 34, 133-141.	1.8	3
43	Evolving Evidence in Idiopathic Intracranial Hypertension. <i>Life</i> , 2021, 11, 1225.	1.1	3
44	One Eye or Two: Statistical Considerations in Ophthalmology With a Focus on Interventional Clinical Trials. <i>Journal of Neuro-Ophthalmology</i> , 2021, 41, 421-423.	0.4	1
45	A new era for giant cell arteritis. <i>Eye</i> , 2020, 34, 1013-1026.	1.1	53
46	2018 Update of the EULAR recommendations for the management of large vessel vasculitis. <i>Annals of the Rheumatic Diseases</i> , 2020, 79, 19-30.	0.5	667
47	Response to "Comment on: "A new era for giant cell arteritis"". <i>Eye</i> , 2020, 34, 1929-1930.	1.1	0
48	Guide to preclinical models used to study the pathophysiology of idiopathic intracranial hypertension. <i>Eye</i> , 2020, 34, 1321-1333.	1.1	9
49	Comment on: British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: reply. <i>Rheumatology</i> , 2020, 59, e163-e164.	0.9	8
50	Calcitonin gene related peptide monoclonal antibody treats headache in patients with active idiopathic intracranial hypertension. <i>Journal of Headache and Pain</i> , 2020, 21, 116.	2.5	24
51	Trends in Optic Neuritis Incidence and Prevalence in the UK and Association With Systemic and Neurologic Disease. <i>JAMA Neurology</i> , 2020, 77, 1514.	4.5	45
52	Emerging themes in idiopathic intracranial hypertension. <i>Journal of Neurology</i> , 2020, 267, 3776-3784.	1.8	27
53	Using Optical Coherence Tomography as a Surrogate of Measurements of Intracranial Pressure in Idiopathic Intracranial Hypertension. <i>JAMA Ophthalmology</i> , 2020, 138, 1264.	1.4	43
54	Reviewing the Recent Developments in Idiopathic Intracranial Hypertension. <i>Ophthalmology and Therapy</i> , 2020, 9, 767-781.	1.0	25

#	ARTICLE	IF	CITATIONS
55	New horizons for idiopathic intracranial hypertension: advances and challenges. British Medical Bulletin, 2020, 136, 118-126.	2.7	23
56	Photopsia. Practical Neurology, 2020, 20, 415-419.	0.5	10
57	European Headache Federation recommendations for neurologists managing giant cell arteritis. Journal of Headache and Pain, 2020, 21, 28.	2.5	31
58	British Society for Rheumatology guideline for diagnosis and treatment of giant cell arteritis. Practical Neurology, 2020, 20, 474-475.	0.5	3
59	<p>Exploring The Current Management Idiopathic Intracranial Hypertension, And Understanding The Role Of Dural Venous Sinus Stenting</p>. Eye and Brain, 2020, Volume 12, 1-13.	3.8	40
60	11 ^β -Hydroxysteroid dehydrogenase type 1 inhibition in idiopathic intracranial hypertension: a double-blind randomized controlled trial. Brain Communications, 2020, 2, fcz050.	1.5	46
61	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis: executive summary. Rheumatology, 2020, 59, 487-494.	0.9	56
62	British Society for Rheumatology guideline on diagnosis and treatment of giant cell arteritis. Rheumatology, 2020, 59, e1-e23.	0.9	128
63	The United Kingdom Neuro-Ophthalmology Superheroes Day 2019. Neuro-Ophthalmology, 2020, 44, 60-62.	0.4	0
64	Idiopathic intracranial hypertension: Update on diagnosis and management. Clinical Medicine, 2020, 20, 384-388.	0.8	29
65	Do Optic Canal Dimensions Measured on CT Influence the Degree of Papilloedema and Visual Dysfunction in Idiopathic Intracranial Hypertension?. Neuro-Ophthalmology, 2019, 43, 3-9.	0.4	9
66	Therapeutic lumbar puncture for headache in idiopathic intracranial hypertension: Minimal gain, is it worth the pain?. Cephalalgia, 2019, 39, 245-253.	1.8	51
67	Association Between Idiopathic Intracranial Hypertension and Risk of Cardiovascular Diseases in Women in the United Kingdom. JAMA Neurology, 2019, 76, 1088.	4.5	79
68	Rapid visual recovery following intravenous tocilizumab in glucocorticoid resistant refractory giant cell arteritis. BMJ Case Reports, 2019, 12, e229236.	0.2	8
69	The Utility of Fundus Fluorescein Angiography in Neuro-Ophthalmology. Neuro-Ophthalmology, 2019, 43, 217-234.	0.4	16
70	A giant escape. Postgraduate Medical Journal, 2019, 95, 346-346.	0.9	1
71	What are the research priorities for idiopathic intracranial hypertension? A priority setting partnership between patients and healthcare professionals. BMJ Open, 2019, 9, e026573.	0.8	48
72	Vogt-Koyanagi-Harada disease. Practical Neurology, 2019, 19, 364-367.	0.5	8

#	ARTICLE	IF	CITATIONS
73	Reviewing the Pathophysiology Behind the Advances in the Management of Giant Cell Arteritis. <i>Ophthalmology and Therapy</i> , 2019, 8, 177-193.	1.0	22
74	Tip of the iceberg in idiopathic intracranial hypertension. <i>Practical Neurology</i> , 2019, 19, 178-179.	0.5	5
75	Differing presenting features of idiopathic intracranial hypertension in the UK and US. <i>Eye</i> , 2019, 33, 1014-1019.	1.1	11
76	United Kingdom CSF Disorders Day 2018. <i>Neuro-Ophthalmology</i> , 2019, 43, 131-134.	0.4	0
77	Optical coherence tomography (OCT) in unconscious and systemically unwell patients using a mobile OCT device: a pilot study. <i>BMJ Open</i> , 2019, 9, e030882.	0.8	20
78	Novel advances in monitoring and therapeutic approaches in idiopathic intracranial hypertension. <i>Current Opinion in Neurology</i> , 2019, 32, 422-431.	1.8	27
79	Enlarged and Enhancing Optic Nerves in Advanced Glial Fibrillary Acidic Protein Meningoencephalomyelitis. <i>Journal of Neuro-Ophthalmology</i> , 2019, 39, 411-415.	0.4	8
80	Giant cell arteritis: new concepts, treatments and the unmet need that remains. <i>Rheumatology</i> , 2019, 58, 1123-1125.	0.9	17
81	Advances in the understanding of headache in idiopathic intracranial hypertension. <i>Current Opinion in Neurology</i> , 2019, 32, 92-98.	1.8	61
82	The expanding burden of idiopathic intracranial hypertension. <i>Eye</i> , 2019, 33, 478-485.	1.1	148
83	A unique androgen excess signature in idiopathic intracranial hypertension is linked to cerebrospinal fluid dynamics. <i>JCI Insight</i> , 2019, 4, .	2.3	55
84	Evaluating the Fat Distribution in Idiopathic Intracranial Hypertension Using Dual-Energy X-ray Absorptiometry Scanning. <i>Neuro-Ophthalmology</i> , 2018, 42, 99-104.	0.4	42
85	Metabolic Concepts in Idiopathic Intracranial Hypertension and Their Potential for Therapeutic Intervention. <i>Journal of Neuro-Ophthalmology</i> , 2018, 38, 522-530.	0.4	78
86	WED 097â€¦Diagnostic lumbar punctures in IIH: what is the patient experience?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A10.2-A10.	0.9	0
87	United Kingdom CSF Disorders Day 2017. <i>Neuro-Ophthalmology</i> , 2018, 42, 414-417.	0.4	0
88	Raised intracranial pressure in those presenting with headache. <i>BMJ: British Medical Journal</i> , 2018, 363, k3252.	2.4	31
89	European Headache Federation guideline on idiopathic intracranial hypertension. <i>Journal of Headache and Pain</i> , 2018, 19, 93.	2.5	111
90	Evaluation and management of adult idiopathic intracranial hypertension. <i>Practical Neurology</i> , 2018, 18, 485-488.	0.5	38

#	ARTICLE	IF	CITATIONS
91	Profile of tocilizumab and its potential in the treatment of giant cell arteritis. Eye and Brain, 2018, Volume 10, 1-11.	3.8	9
92	Characterising the patient experience of diagnostic lumbar puncture in idiopathic intracranial hypertension: a cross-sectional online survey. BMJ Open, 2018, 8, e020445.	0.8	37
93	Idiopathic intracranial hypertension: consensus guidelines on management. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 1088-1100.	0.9	303
94	Loss of vision. , 2018, , .		1
95	The red eye. , 2018, , .		0
96	United Kingdom CSF Disorders Day, 14th October 2016, University Hospitals Birmingham. Neuro-Ophthalmology, 2017, 41, 161-163.	0.4	0
97	A Genome-wide Association Study Identifies Risk Alleles in Plasminogen and P4HA2 Associated with Giant Cell Arteritis. American Journal of Human Genetics, 2017, 100, 64-74.	2.6	78
98	Randomised controlled trial of bariatric surgery versus a community weight loss programme for the sustained treatment of idiopathic intracranial hypertension: the Idiopathic Intracranial Hypertension Weight Trial (IIH:WT) protocol. BMJ Open, 2017, 7, e017426.	0.8	63
99	What Do Transgender Patients Teach Us About Idiopathic Intracranial Hypertension?. Neuro-Ophthalmology, 2017, 41, 326-329.	0.4	35
100	The use of transdermal optical coherence tomography to image the superficial temporal arteries. Eye, 2017, 31, 157-160.	1.1	8
101	Development and validation of a questionnaire assessing the quality of life impact of Colour Blindness (CBQoL). BMC Ophthalmology, 2017, 17, 179.	0.6	19
102	Segmentation error in spectral domain optical coherence tomography measures of the retinal nerve fibre layer thickness in idiopathic intracranial hypertension. BMC Ophthalmology, 2017, 17, 257.	0.6	24
103	The Ocular Glymphatic System and Idiopathic Intracranial Hypertension: Author Response to 'Hypodense Holes and the Ocular Glymphatic System', 2017, 58, 1134.		14
104	INTERDISCIPLINARY CONSENSUS ON THE MANAGEMENT OF IIH IN THE UK. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.159-e1.	0.9	1
105	Understanding idiopathic intracranial hypertension: mechanisms, management, and future directions. Lancet Neurology, The, 2016, 15, 78-91.	4.9	321
106	Evolving evidence in adult idiopathic intracranial hypertension: pathophysiology and management. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 982-992.	0.9	173
107	Headache determines quality of life in idiopathic intracranial hypertension. Journal of Headache and Pain, 2015, 16, 521.	2.5	79
108	Cranial ultrasound for the diagnosis of giant cell arteritis. A retrospective cohort study. Journal of the Royal College of Physicians of Edinburgh, The, 2015, 45, 268-272.	0.2	18

#	ARTICLE	IF	CITATIONS
109	Sight-threatening pseudotumour cerebri associated with excess vitamin A supplementation. <i>Practical Neurology</i> , 2015, 15, 72-73.	0.5	10
110	Increase in admissions related to giant cell arteritis and polymyalgia rheumatica in the UK, 2002-13, without a decrease in associated sight loss: potential implications for service provision. <i>Rheumatology</i> , 2015, 54, 375-377.	0.9	15
111	Treating Idiopathic Intracranial Hypertension. <i>JAMA Neurology</i> , 2014, 71, 1326.	4.5	2
112	Idiopathic Intracranial Hypertension. <i>JAMA - Journal of the American Medical Association</i> , 2014, 312, 1059.	3.8	7
113	A practical approach to, diagnosis, assessment and management of idiopathic intracranial hypertension. <i>Practical Neurology</i> , 2014, 14, 380-390.	0.5	76
114	Aspirin as adjunctive treatment for giant cell arteritis. <i>The Cochrane Library</i> , 2014, , CD010453.	1.5	26
115	Mitomycin C in the treatment of a Schneiderian (inverted) papilloma of the lacrimal sac. <i>International Ophthalmology</i> , 2010, 30, 303-305.	0.6	19
116	Idiopathic Intracranial Hypertension Associated with Iron Deficiency Anaemia: A Lesson for Management. <i>European Neurology</i> , 2009, 62, 105-108.	0.6	50
117	Intracranial dermoid cyst presenting as an isolated fourth nerve palsy. <i>Journal of Neurology</i> , 2009, 256, 820-821.	1.8	7
118	Incidence of endophthalmitis following vitreoretinal surgery. <i>International Ophthalmology</i> , 2009, 29, 203-205.	0.6	18
119	Aetiology and outcomes of adult superior oblique palsies: a modern series. <i>Eye</i> , 2009, 23, 640-644.	1.1	56
120	Accuracy of Goldmann, ocular response analyser, Pascal and TonoPen XL tonometry in keratoconic and normal eyes. <i>British Journal of Ophthalmology</i> , 2008, 92, 1661-1665.	2.1	66
121	Postcataract endophthalmitis: Incidence and microbial isolates in a United Kingdom region from 1996 through 2004. <i>Journal of Cataract and Refractive Surgery</i> , 2007, 33, 265-268.	0.7	68
122	A Transilluminating Scleral Lesion. <i>JAMA Ophthalmology</i> , 2006, 124, 1504.	2.6	0
123	Does use of isotretinoin rule out a career in flying?. <i>British Journal of Ophthalmology</i> , 2006, 90, 957-959.	2.1	23